Skip to content
value.today

Biolinq Inc

🇺🇸 San Diego, California, USABiotechnologyFounded 2012
Total raised
$179 M
4 rounds on record
Latest round
$90 M
Mar 2025
First round on record
Nov 2017
Today
Private
No later event on record

Funding rounds

4 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Biolinq Inc
MonthRaisedRaiseSizeInvestorsSoldFiling
Mar 2025$90 MNo. 4$50 to $250 million

Biolinq Inc: Raise no. 4, Mar 2025

Investors in this round

45 investors had bought by the notice of Mar 21, 2025: 45 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$90 M of $100 M offered; $10 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • David Affas Arida · Executive Officer
  • Jared Affas Tangney · Executive Officer
  • Richard Yang · Executive Officer, Director
  • Chris Dimitropoulos · Director
  • Dan Bradbury · Director
  • David Affas Berry · Director
  • Derek Rapp · Director
  • Thad Johnson · Director
  • Zina Affas Besse · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by M. Andrew Woodmansee, Vice President, Legal Affairs. Source: SEC Form D, newest notice filed Mar 21, 2025. Read the notice at the SEC.

equitySEC
Sep 2021$78 MNo. 3$50 to $250 million

Biolinq Inc: Raise no. 3, Sep 2021

Investors in this round

62 investors had bought by the notice of Jun 1, 2022: 62 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$78 M of $106 M offered; $28 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$1,558,437
Finders' fees
none
Paid to its own people
$35,000 (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Jared Tangney · Executive Officer
  • Richard Yang · Executive Officer, Director
  • Dan Bradbury · Director
  • Nancy Hong · Director
  • Thad Johnson · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Thomas Mark Cibotti (CRD 4672417) · broker-dealer Covington Associates, LLC (CRD 127437) · Boston, MassachusettsSold in CA, CO, CT, FL, MO, NY, TX, WA

Remarks in the notice

  • On the use of proceeds: “The closing of the financing triggered the payment of such amount as deferred compensation.”

Signed by Richard Yang, Chief Executive Officer. Source: SEC Form D and 1 amendment, newest notice filed Jun 1, 2022. Read the notice at the SEC.

equitySEC
Mar 2019$3 MNo. 2$2 to $10 million

Biolinq Inc: Raise no. 2, Mar 2019

Investors in this round

9 investors had bought by the notice of Mar 20, 2019: 9 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$3 M of $3 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Jared Tangney · Executive Officer, Director, Promoter
  • Joshua Windmiller · Executive Officer, Director, Promoter
  • Daniel Bradbury · Director
  • Edward Kliphuis · Director
  • Lana Ghanem · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Jared Tangney, Ceo. Source: SEC Form D, newest notice filed Mar 20, 2019. Read the notice at the SEC.

equitySEC
Nov 2017$8 MNo. 1$2 to $10 million

Biolinq Inc: Raise no. 1, Nov 2017

Investors in this round

17 investors had bought by the notice of Nov 27, 2017: 17 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$8 M of $13 M offered; $5 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Jared Tangney · Executive Officer, Director, Promoter
  • Joshua Windmiller · Executive Officer, Director, Promoter
  • Edward Kliphuis · Director
  • Lana Ghanem · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Jared Tangney, Ceo. Source: SEC Form D, newest notice filed Nov 27, 2017. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Biolinq Inc chose not to state its revenue in its newest notice of a funding round (Mar 2025).

    SEC Form D · Mar 2025

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Mar 2025

That is all the official record says: Biolinq Inc has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Biolinq Inc is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 4 rounds above had up to 62 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Biolinq Inc
NameRoleNamed in
David Affas AridaExecutive officerMar 2025
Jared Affas TangneyExecutive officerMar 2025
Richard YangExecutive officerMar 2025
Jared TangneyExecutive officerJun 2022
Joshua WindmillerExecutive officerSep 2021
Chris DimitropoulosDirectorMar 2025
Dan BradburyDirectorMar 2025
David Affas BerryDirectorMar 2025
Derek RappDirectorMar 2025
Richard YangDirectorMar 2025
Thad JohnsonDirectorMar 2025
Zina Affas BesseDirectorMar 2025
Nancy HongDirectorJun 2022
Daniel BradburyDirectorMar 2019
Edward KliphuisDirectorMar 2019
Jared TangneyDirectorMar 2019
Joshua WindmillerDirectorMar 2019
Lana GhanemDirectorMar 2019
Jared TangneyPromoterMar 2019
Joshua WindmillerPromoterMar 2019